ArticleClinical and vaccine immunology : CVI2016
Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen.
Article in Clinical and vaccine immunology : CVI, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Functional antibody responses and protection against symptomatic dengue.Communications medicine · 2026Review
- Computational discovery of DENV-3 RdRp allosteric inhibitors: biological evaluation and mechanistic studies.Molecular diversity · 2026Article
- Abdominal Symptoms During the Febrile Phase Indicate Profound Innate Immune Responses in Dengue.Biology · 2026Article
- Integrative immunogenomic strategy for designing a multi-epitope vaccine against Zika and Dengue viruses.Scientific reports · 2026Article
- Review
- B-cell epitope mapping of Orthoflavivirus zikaense in mother-newborn immune interaction reveals postnatal immune signatures.Scientific reports · 2025Article
- Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates.Journal of microbiology (Seoul, Korea) · 2025Review
- The Flavivirus Non-Structural Protein 5 (NS5): Structure, Functions, and Targeting for Development of Vaccines and Therapeutics.Vaccines · 2024Review
- Article
- Designing an Epitope-Based Peptide Vaccine Derived from RNA-Dependent RNA Polymerase (RdRp) against Dengue Virus Serotype 2.Vaccines · 2022Article
- Humoral immune response induced with dengue virus-like particles serotypes 1 and 4 produced in silkworm.AMB Express · 2022Article
- Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.Medical microbiology and immunology · 2021Review
- SARS-CoV-2 vaccine development and how Brazil is contributing.Genetics and molecular biology · 2021Article
- Dengue Virus Non-Structural Protein 5 as a Versatile, Multi-Functional Effector in Host-Pathogen Interactions.Frontiers in cellular and infection microbiology · 2021Review
- An Overview of Current Uses and Future Opportunities for Computer-Assisted Design of Vaccines for Neglected Tropical Diseases.Advances and applications in bioinformatics and chemistry : AABC · 2021Review
- Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced inVaccines · 2020Review
- Production of dengue virus-like particles serotype-3 in silkworm larvae and their ability to elicit a humoral immune response in mice.AMB Express · 2020Article
- Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?Pathogens (Basel, Switzerland) · 2020Review
- Transcutaneous Administration of Dengue Vaccines.Viruses · 2020Article
- Protective Immunity to Dengue Virus Induced by DNA Vaccines Encoding Nonstructural Proteins in a Lethal Challenge Immunocompetent Mouse Model.Frontiers in medical technology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue fever is caused by any of the four known dengue virus serotypes (DENV1 to DENV4) that affect millions of people worldwide, causing a significant number of deaths. There are vaccines based on chimeric viruses, but they still are not in clinical use. Anti-DENV vaccine strategies based on nonstructural proteins are promising alternatives to those based on whole virus or structural proteins. The DENV nonstructural protein 5 (NS5) is the main target of anti-DENV T cell-based immune responses in humans. In this study, we purified a soluble recombinant form of DENV2 NS5 expressed in Escherichia coli at large amounts and high purity after optimization of expression conditions and purification steps. The purified DENV2 NS5 was recognized by serum from DENV1-, DENV2-, DENV3-, or DENV4-infected patients in an epitope-conformation-dependent manner. In addition, immunization of BALB/c mice with NS5 induced high levels of NS5-specific antibodies and expansion of gamma interferon- and tumor necrosis factor alpha-producing T cells. Moreover, mice immunized with purified NS5 were partially protected from lethal challenges with the DENV2 NGC strain and with a clinical isolate (JHA1). These results indicate that the recombinant NS5 protein preserves immunological determinants of the native protein and is a promising vaccine antigen capable of inducing protective immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.